Alena Janda Markmann, MD, PhD
Assistant Professor of Medicine, Division of Infectious Diseases
Areas of Interest
New and emerging viruses, Arboviruses, Virology, Immunology, Antibody structure and function
About
As a clinician scientist, Dr. Markmann’s has developed a research interest in the morbidity and global public health burden of new and emerging viruses. Her current research interests include studying human immune responses to Zika and dengue viruses, with a specific focus on B cell and antibody responses. Dr. Markmann has a clinical passion for caring for individuals who suffer from all types of infectious diseases across a broad clinical spectrum. Seeing and taking care of patients is very rewarding and gives her an important perspective on the patient and healthcare side of medicine that she can apply to her research.
In the news
The 4th Annual Global Health Scholars Symposium—sponsored by the Institute for Global Health and Infectious Diseases and the Gillings School of Global Public Health—opened February 13 recognizing the resilience of UNC’s global health programs and the enduring partnerships that withstand today’s challenging landscape. The event brought together trainees, faculty, and partners to showcase research across … Read more Dr. Ross Boyce, a researcher with the UNC Institute for Global Health and Infectious Diseases, tested a military uniform treatment idea on wraps used to carry babies in many parts of Africa and South America. Would treating these baby wraps with permethrin protect babies in Uganda from malaria? The answer was yes. In a six-month … Read more William A. Fischer II, MD, Director of Emerging Pathogens at UNC’s Institute for Global Health and Infectious Diseases and Joe Eron, MD, UNC Chief of Infectious Diseases and chair of the ACTG, co-authored a study that found tecovirimat used to treat mpox does not shorten time to lesion resolution, reduce pain, or speed viral clearance … Read more A trial led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, marks a significant milestone toward what could become the first complete long‑acting HIV regimen requiring dosing only twice per year. This new report is considered the first Phase 2 study to evaluate a complete HIV‑1 treatment … Read more
Resilience in Global Health: Inside UNC’s 4th Annual Global Health Scholars Symposium
Sawyer Accelerates the Fight Against Childhood Malaria
Key International Mpox Trial Finds No Clinical Benefit from Tecovirimat
Twice‑Yearly Injectable HIV Regime Treatment Demonstrates Strong Efficacy and Safety
Education
-
Undergraduate
University of Rochester
-
Medical School
Albert Einstein College of Medicine
-
Residency
The Mount Sinai Hospital
-
Fellowship
University of North Carolina at Chapel Hill
-
PhD
Albert Einstein College of Medicine